Molluscum Contagiosum

Molluscum contagiosum is a common, benign viral skin infection caused by the molluscum contagiosum virus (MCV), a double-stranded DNA poxvirus in the genus Molluscipoxvirus — genotype MCV-1 accounts for roughly 90% of cases in children, while MCV-2 is seen more often with sexual transmission in adults and in immunocompromised patients.^[1] It is limited to the skin and, occasionally, the oral mucosa, and occurs commonly in 3 quite different groups: healthy children (most often between about 1 and 10 years of age), sexually active adults, and immunocompromised patients of any age.^[2][3] After an incubation period that Canadian sources describe as genuinely variable — roughly 2 weeks to 6 months from skin contact with the virus to the first visible bump — small, painless papules appear and grow over several weeks into the classic firm, smooth, pinkish-white or flesh-coloured lesions, often with a small central pit.^[4][2] Most children develop somewhere between 1 and 20 lesions at a time, though some develop many more.^[3] The single most important message for a pharmacist to deliver accurately is that molluscum contagiosum is self-limited in a person with a normal immune system: lesions typically clear on their own, without scarring, over a period ranging from several months to about 2-3 years, and current Canadian evidence-based review concludes that no available treatment has been clearly shown to outperform simply awaiting spontaneous resolution — making watchful waiting a genuinely reasonable first choice for most patients.^[2][5][6] Where the pharmacist's role adds the most value is elsewhere: teaching hygiene measures that limit spread, correctly distinguishing 2 reassuring but alarming-looking findings (the "beginning of the end" immune response and an eczematous "id" reaction around the lesions) from an actual secondary bacterial infection, and recognizing the minority of patients — extensive or atypical disease, especially in an adult with no other explanation — in whom molluscum can be an early clue to underlying immunosuppression.

The classic lesion

A molluscum papule is firm, smooth-surfaced, and dome-shaped, typically 2-5 mm across, ranging in colour from flesh-toned to pink or pearly white. Its defining feature is a small central dell or umbilication, which on close inspection (a dermatoscope is genuinely useful for very small or early lesions) contains a white, cheesy, keratinous plug — the compacted intracytoplasmic viral inclusions known histologically as molluscum bodies, or Henderson-Paterson bodies, though biopsy is rarely needed to make this diagnosis.^[1][7]

Typical flesh-coloured, dome-shaped, pearly molluscum contagiosum papules, several showing the characteristic central umbilication. (E van Herk, CC BY-SA 3.0, Wikimedia Commons)

Number and distribution

Lesion counts vary widely: most children have somewhere between 1 and 20 papules at a time, though some develop hundreds, particularly with ongoing autoinoculation or an underlying immunocompromising condition.^[3] In children, lesions cluster in characteristic flexural sites — the axillae, antecubital and popliteal fossae, and groin/crural folds — as well as the trunk, face, and extremities more generally.^[2] In sexually active adults, genital transmission produces a different, sexually-transmitted-infection-typical distribution: the lower abdomen, groin, external genitals, buttocks, and inner thighs.^[4] Autoinoculation — spreading the virus from one lesion to a new site by scratching, rubbing, or shaving over it — is the dominant driver of new lesions within an already-affected person, which is exactly why hands-off counselling matters as much as any specific treatment choice.^[2][4]

A cluster of molluscum lesions — grouping like this typically reflects autoinoculation from scratching or rubbing an earlier lesion. (Evanherk, CC BY-SA 3.0, Wikimedia Commons)

Two reassuring findings that are easy to mistake for infection

Two changes in the appearance of an existing lesion are common, genuinely benign, and frequently mistaken for a worsening infection:

• The "Beginning Of The End" (BOTE) sign — a lesion becomes inflamed, red, and sometimes pustular-looking as the host immune system finally recognizes and starts clearing the virus. This is a reassuring finding, not a reason for antibiotics, provided there is no fever, increasing pain, or expanding surrounding erythema/warmth to suggest a true secondary bacterial (usually staphylococcal or streptococcal) skin infection, which does need antibiotic treatment.^[2]
• Molluscum dermatitis (an eczematous "id" reaction) — red, rough, eczema-like skin developing around (not on) the molluscum papules, seen in roughly 1 in 10 affected children. This represents an immune-mediated hypersensitivity reaction to MCV antigens, not a spreading infection, and its appearance is often itself a harbinger that the body is beginning to clear the virus.^[8][7]

• Age: most common in children roughly 1-10 years old, with a median age at diagnosis around 5 years; global paediatric prevalence estimates range from about 5% to 11.5%.^[1][3]
• Atopic dermatitis/eczema is one of the strongest modifiers of disease burden: a disrupted skin barrier makes viral entry easier, and frequent scratching drives more extensive autoinoculation, so children with eczema tend to develop more numerous lesions that persist longer than in children with normal skin — one cited study found a personal history of eczema in 62% of children with molluscum.^[7][1]
• Close-contact settings — daycare, school, contact sports, and shared swimming/bathing facilities — favour transmission through direct skin contact and contaminated shared items such as towels, kickboards, and bath sponges.^[2][4]
• Sexual activity in adults: genital and lower-abdominal/groin molluscum in a sexually active adult spreads the same way as any other skin-to-skin sexually transmitted infection, including through contact that does not involve penetration.^[4]
• Immunosuppression meaningfully raises both the burden and persistence of disease: prevalence reaches roughly 20% in people with HIV, about 7% in solid-organ transplant recipients, and roughly 0.5% in children being treated for cancer; biologic therapy and chronic systemic corticosteroid use are similarly associated with more extensive disease.^[7]
• Warm, humid climates and crowded living conditions are both associated with higher community prevalence.

Diagnosis is clinical

Molluscum contagiosum is diagnosed by its appearance: a firm, smooth, dome-shaped papule with a central umbilication, most reliably confirmed on close inspection or with a dermatoscope for smaller lesions.^[1][7] No laboratory testing or imaging is routinely required.

History

• Onset, duration, number of lesions, and whether new lesions have appeared in clusters near an existing one (suggesting autoinoculation).
• Household, daycare, school, or sexual contact with someone with similar lesions.
• Personal history of atopic dermatitis/eczema, and current pruritus or scratching behaviour.
• Immune status — HIV status if unknown and relevant, transplant history, chemotherapy, biologic therapy, or chronic corticosteroid use.
• For a sexually active adult with anogenital lesions, a routine sexual history and sexually-transmitted-infection risk assessment.

When testing is actually used

Biopsy (looking for the characteristic molluscum/Henderson-Paterson bodies on histology) or PCR is reserved for atypical presentations, diagnostic uncertainty, or extensive/giant lesions in an immunocompromised patient — in advanced HIV disease specifically, disseminated cutaneous cryptococcosis can closely mimic molluscum, and biopsy is used to tell the two apart.^[1]

Differential diagnosis

• Confirm the diagnosis clinically and set an accurate, evidence-based expectation from the first visit: most cases in an immunocompetent person clear on their own, without scarring, over months to a couple of years.^[2][5]
• Reduce spread — both autoinoculation to new sites on the same person, and transmission to household, daycare/school, or sexual contacts.
• Relieve itch and discomfort, particularly where molluscum dermatitis or background eczema is present, without using therapy strong enough to suppress the immune response that is actually clearing the virus.
• For patients who choose active treatment, achieve clearance while minimizing pain, scarring, and pigment change, especially in young children.
• Correctly distinguish the 2 reassuring findings described in Recognize the Condition (the BOTE sign and molluscum dermatitis) from an actual secondary bacterial infection that needs antibiotics.
• Recognize the minority of patients who need to move beyond routine self-care: immunocompromised patients, giant/atypical/refractory lesions, periocular disease, and diagnostic uncertainty.

• Present watchful waiting explicitly as a valid option, not a last resort — most cases clear on their own within about a year, and the substantial majority within 2-3 years, without scarring.^[5][2]
• Wash hands frequently, and encourage the patient not to rub, scratch, pick at, or shave over lesions — scratching is the main way the virus spreads from one part of the body to another (autoinoculation).^[3][2]
• Do not share towels, face cloths, clothing, or other personal items; clean shared toys and sports equipment frequently.^[4][2]
• Cover visible lesions with a watertight bandage for swimming; loose gauze is a reasonable alternative for a child who scratches, since prolonged tight occlusion of a lesion can itself cause skin breakdown and scarring.^[3]
• Treat any eczema or rash around the lesions (see Special Populations) — this reduces the itch that drives scratching-related spread as much as it treats the rash itself.^[2]
• Daycare and school attendance: Canadian guidance is genuinely permissive. Once a lesion has been identified as molluscum, the child can continue to attend, provided reasonable hygiene precautions (hand hygiene, not sharing personal items, covering lesions for swimming) are followed — this is not an excludable condition.^[3]
• For a sexually active adult with genital lesions, avoid sexual contact with an uninfected partner until lesions have cleared, or use barrier protection, and consider screening for other sexually transmitted infections.^[4]

Pediatrics

Children are both the population in which molluscum is most common and the one in which watchful waiting is most often the right first conversation — most cases in a healthy child resolve without treatment or scarring.^[2][5] When a family wants active treatment, favour the least painful options first in young children: home-applied potassium hydroxide or tretinoin, or in-office cantharidin (whose application is painless even though the resulting blister is not) rather than cryotherapy or curettage, which are frequently poorly tolerated at this age.^[2][9] Anogenital lesions in a young child most often reflect ordinary autoinoculation from molluscum elsewhere on the body rather than sexual contact, but still warrant the same careful, context-driven clinical assessment applied to any anogenital finding in a child, rather than an automatic assumption in either direction.

Atopic dermatitis / eczema

Children with a personal history of eczema develop more numerous molluscum lesions that persist longer, because a disrupted skin barrier eases viral entry and frequent scratching drives more extensive autoinoculation.^[7][1] A related but distinct finding — molluscum dermatitis, an eczematous "id" reaction around (not on) the papules — occurs in roughly 1 in 10 affected children and represents an immune-mediated hypersensitivity response to the virus rather than a worsening infection; it often does not need treatment beyond a plain emollient, and when it is itchy enough to need more, a short course (up to about 2 weeks) of a low-potency topical corticosteroid such as hydrocortisone 1% or desonide 0.05%, applied specifically to the surrounding dermatitis and not to the molluscum papules themselves, is appropriate.^[8][2] A genuinely important teaching point follows directly from this: topical corticosteroids or other immunomodulators applied onto the molluscum lesions (rather than around them) can suppress the very immune response that is clearing the virus and may potentiate its spread, so any background eczema flare elsewhere on the body should also be managed carefully around, not over, active molluscum lesions.^[8]

Pregnancy and breastfeeding

Sexually active adults

Genital or lower-abdominal/groin molluscum in an adult is usually sexually transmitted, spreading through direct skin contact that does not require penetration.^[4] Screen for other sexually transmitted infections, counsel on avoiding sexual contact with an uninfected partner (or using barrier protection) until lesions clear, and keep condyloma acuminatum (genital warts) on the differential, since both are common causes of genital papules in this population (see Assessment & Diagnosis).

Immunocompromised patients

HIV infection, solid-organ transplantation, active chemotherapy, biologic therapy, and chronic systemic corticosteroid use are all associated with more numerous, larger (including giant, greater than 1 cm), and more treatment-refractory molluscum lesions, with a genuinely lower likelihood of spontaneous resolution than in an immunocompetent patient.^[7][1] Favour active treatment over watchful waiting in this group, keep the threshold low for dermatology referral, and consider that extensive, atypical, or giant molluscum with no other identified cause of immunosuppression can be an early clinical marker of HIV — a reason to consider HIV testing rather than simply escalating molluscum-directed therapy.^[2][7][1]

• For patients choosing watchful waiting, no active monitoring visit is required; advise the family to return if lesions have not resolved within about 2-3 years, if the pattern changes, or if any red flag described above develops.^[2]
• For a home-applied topical (potassium hydroxide or tretinoin), reassess technique and tolerability at around 2-4 weeks — confirm the product is being applied to the lesion only, not the surrounding skin, since this is the most common reason for both irritation and an apparently slow response.
• For cryotherapy or cantharidin, expect a gradual reduction in lesion count over several treatment cycles (every 1-4 weeks depending on modality) rather than full clearance after a single visit; at least 2 cantharidin treatments are typically needed.^[9]
• For molluscum dermatitis treated with a short course of low-potency topical corticosteroid, reassess at about 2 weeks; persistence beyond this warrants dermatology referral rather than simply continuing or escalating the steroid.^[2]
• At any visit, confirm the family can tell the difference between the reassuring BOTE sign and molluscum dermatitis on one hand, and a true secondary bacterial infection (fever, increasing pain, expanding erythema/warmth) on the other, since this distinction determines whether reassurance or antibiotics is the right next step.^[2]

1. Confirm the diagnosis is genuinely molluscum and not one of its mimics (see Assessment & Diagnosis) — a lesion that "fails" standard therapy is sometimes simply not molluscum.
2. Confirm technique and adherence before concluding a therapy has failed: was a home-applied product used only on the lesion itself, was the full course actually completed, and for cryotherapy/curettage/cantharidin, were treatment intervals actually attended?
3. If a single home-applied or in-office modality is responding slowly, moving to or combining with a physical destructive option (cryotherapy or curettage) offers the highest, most consistent clearance rates reported in Canadian evidence review.^[5]
4. In an immunocompromised patient with refractory disease, address the underlying driver directly where possible (for example, optimizing antiretroviral therapy in HIV) — resolution is genuinely less likely from molluscum-directed therapy alone while the underlying immunosuppression remains unaddressed.^[7]
5. If molluscum dermatitis persists beyond an adequate 2-week trial of a low-potency topical corticosteroid and emollient, refer to dermatology rather than escalating corticosteroid potency independently.^[2]
6. Extensive, atypical, refractory, or giant molluscum with no other explanation, particularly in an adult: consider HIV testing/immunodeficiency evaluation rather than continuing to cycle through molluscum-directed treatments alone.^[2][7]
7. Diagnostic uncertainty at any point: refer for biopsy rather than continuing empiric treatment.

• Applying a topical corticosteroid or immunomodulator directly onto molluscum papules rather than the surrounding skin — this can suppress the immune response that clears the virus and may potentiate its spread.^[8]
• Treating the "beginning of the end" (BOTE) sign as if it were a secondary bacterial infection and reaching for antibiotics without fever, increasing pain, or expanding erythema to actually support that diagnosis.^[2]
• Recommending imiquimod out of habit — current evidence review shows no clinical benefit over vehicle/placebo and more application-site reactions.^[6][5]
• Presenting watchful waiting as a lesser or default option rather than a genuinely evidence-based first choice.^[5][6]
• Excluding a child from daycare or school over molluscum once it has been identified — Canadian guidance does not support this as long as reasonable hygiene precautions are followed.^[3]
• Using aggressive destructive treatment (cryotherapy, curettage) on the face or around the eyes without specialist involvement, given the higher stakes for scarring and pigment change there.
• Missing extensive, atypical, or giant molluscum in an adult as a possible early clue to HIV or another cause of immunosuppression.^[2][7]
• Reflexively treating anogenital molluscum in a young child as a sign of abuse without the broader clinical context, given that autoinoculation usually explains it.
• Not counselling on autoinoculation and hygiene (no scratching/shaving, no shared towels, covering lesions for swimming) alongside whichever active treatment is chosen.^[2][4]

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Home-Applied Topical Options

A reasonable first active-treatment choice for a family that wants to do something rather than simply observe. Apply to individual molluscum papules only, not surrounding normal skin.

In-Office Physical Destruction — Most Consistently Effective

The highest, most consistently effective options in Canadian evidence review, at the cost of real pain and a genuine risk of scarring or pigment change.

Cantharidin and Emerging Agents

Cantharidin has been a genuine Canadian in-office option for years; berdazimer is a newer US-approved at-home option not yet established in Canada.

Managing Molluscum Dermatitis (Eczematous Id Reaction) — Treats the Skin Around the Lesions, Not the Lesions Themselves

For the eczematous reaction that can develop around molluscum papules. Apply only to the surrounding affected skin; never onto the molluscum lesions themselves.

Not Recommended

Listed to state explicitly that this is not a preferred choice, not as a routine option.